# Vanderbilt HIV Clinical Trials Unit (CTU)

> **NIH NIH UM1** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $2,577,612

## Abstract

PROJECT SUMMARY/ABSTRACT
The HIV pandemic is one of the greatest ongoing threats to health and development, over 35 years past its
recognition. The NIAID-funded Clinical Trials Networks have played critical roles in the coordinated response to
key research questions in the HIV/AIDS field, which will contribute to ultimately ending the HIV epidemic. The
Vanderbilt HIV Clinical Trials Unit (CTU) will continue the established partnership between Vanderbilt University
Medical Center in Nashville, Tennessee, and Washington University in St. Louis, Missouri, which are located in
a region of the United States with high incidence and prevalence of HIV. This CTU comprises three highly
productive Clinical Research Sites (CRSs) that contribute to three Networks - the therapeutics mission of the
AIDS Clinical Trials Group (ACTG), the vaccine mission of the HIV Vaccine Trials Network (HVTN), and the non-
vaccine prevention mission of the HIV Prevention Trials Network (HPTN). The Vanderbilt Vaccine CRS and
Washington University Therapeutics CRS have been members of the HVTN and ACTG since the inception of
these Networks in 1987-1988. The Vanderbilt Therapeutics CRS joined the ACTG in 2000. To contribute more
broadly to the Networks, Washington University has provided protocol-specific enrollment to the HPTN since
2016, and proposes to become a full member site of the HPTN, as the Washington University Prevention &
Therapeutics CRS. Leaders of this CTU have made high-impact scientific and programmatic contributions to the
Networks in areas that include human genomics, contemporary HIV-associated comorbidities, neurological
aspects of HIV disease, immunology of vaccine response, and beyond. During the proposed funding period, the
Vanderbilt CTU will continue to make substantial contributions to the ACTG, HVTN and HPTN's scientific
priorities. ACTG sites at both Vanderbilt and Washington University will focus on strategies to improve the health
of people living with HIV/AIDS, tuberculosis, and viral hepatitis. The Vanderbilt HVTN site will contribute both
study participants and cutting-edge immunologic technologies to further the major scientific priority of developing
and testing a safe and effective vaccine for HIV. The Washington University site will additionally contribute to
HPTN's emphasis on long-acting agents for pre-exposure prophylaxis, developing multipurpose technologies
such as combining HIV prevention with contraception, and strategies integrating biomedical, behavioral and
structural interventions for prevention. All CRSs of this CTU have an established record of success in enrolling
participants to clinical trials and conducting studies with utmost fidelity to ensure participant safety and quality
data advancing the science of HIV treatment and prevention.

## Key facts

- **NIH application ID:** 10055867
- **Project number:** 2UM1AI069439-16
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** David W Haas
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,577,612
- **Award type:** 2
- **Project period:** 2007-02-01 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10055867

## Citation

> US National Institutes of Health, RePORTER application 10055867, Vanderbilt HIV Clinical Trials Unit (CTU) (2UM1AI069439-16). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10055867. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*